Wave Life Sciences: director Verdine Gregory L. received 74,700 shares

What happened Verdine Gregory L., a director of Wave Life Sciences, received 10,700 restricted stock units and was granted a derivative award (option) covering 64,000 shares on Oct 5, 2026. Both items are reported at a price of $0.00 and a total reported value of $0.

Key details

• Transaction date: Oct 5, 2026. Filing date: Oct 7, 2026.
• RSU: 10,700 shares granted at $0.00 (code A). Vesting: 100% on the earlier of the company's 2027 annual meeting of stockholders or Oct 5, 2027 (footnote F1).
• Option/derivative: 64,000 shares granted at $0.00 (code A, derivative). Vesting: 100% on the earlier of the company's 2027 annual meeting of stockholders or Oct 5, 2027 (footnote F3).
• Shares owned after the transaction: not stated in the provided filing details.
• Footnote on existing holdings (F2): Consists of shares held in a trust by Lynet Holdings LLC; the reporting person is sole manager of Lynet Holdings LLC and settlor of the trust and may be deemed to have shared voting and investment power, but disclaims beneficial ownership except to the extent of his pecuniary interest.
• Remarks: The filing notes a corporate redomiciliation where Wave Life Sciences, Inc. became the successor to Wave Life Sciences Ltd. on Aug 7, 2026.
• Exhibit: 24.1 power of attorney included.

Why it may matter

• These entries are grants: restricted stock unit awards and an option grant, not exercises or market sales.
• The option grant is not reported as an exercise or sale and no cashless exercise is indicated.
• The trust disclosure describes potential shared voting or investment power, not an outright beneficial ownership statement.
• The filing does not show why the insider traded or why the company acted.